



Regulated information

25 April 2014

Fidelta announces integrated drug discovery collaboration with LEO Pharma

Zagreb, Croatia, 25th April 2014 – Fidelta, a Galapagos company, announced today that it has signed an integrated drug discovery collaboration agreement with LEO Pharma. Under the terms of the agreement, Fidelta will apply its extensive drug discovery expertise to an undisclosed target within LEO Pharma’s dermatology drug discovery portfolio.

Phil Dudfield, Managing Director, Fidelta commented, “We are delighted about the contract with LEO Pharma, one of the leading research-based pharmaceutical companies and a new client for Fidelta. It is testament to the strength and depth of Fidelta’s drug discovery capabilities and expertise in chemistry and pharmacology. Fidelta continues to build its client base and execute further on its planned growth path.”

Thorsten Thormann, Senior Vice President, New Product Discovery at LEO Pharma: “LEO Pharma wishes to provide more new treatment solutions to people with skin diseases even faster. In order to achieve this, we wish to collaborate with partners that give us access to new expertise, knowledge and technology within our field. The collaboration with Fidelta is a step that contributes to strengthen our R&D strategy”.

About Fidelta

Fidelta, a subsidiary of Galapagos NV, is a fee-for-service, collaborative drug discovery organization that combines expertise in the areas of chemistry, pharmacology, ADME, pharmacokinetics and toxicology. Fidelta offers fully integrated services, as well as flexible stand-alone solutions for projects in discovery and early pre-clinical development.

Fidelta’s objective is to deliver efficacious, safe and differentiated pre-clinical candidates for its clients. For more information, visit www.fidelta.eu.

About LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions.

Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide.

For more information, visit www.leo-pharma.com.

More information:

Fidelta d.o.o.
Adrijana Vinter, Business Development Manager
Tel: +385 1 8886395
fidelta@glpg.com

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Fidelta, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Fidelta expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.